financetom
Business
financetom
/
Business
/
Humana's Q1 Adjusted Earnings Fall, Revenue Rises; 2024 Adjusted EPS Outlook Reaffirmed
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Humana's Q1 Adjusted Earnings Fall, Revenue Rises; 2024 Adjusted EPS Outlook Reaffirmed
Apr 24, 2024 4:50 AM

07:30 AM EDT, 04/24/2024 (MT Newswires) -- Humana (HUM) reported Q1 adjusted earnings Wednesday of $7.23 per share, down from $9.38 a year earlier.

Analysts polled by Capital IQ expected $6.

Revenue for the quarter ended March 31 was $29.61 billion, up from $26.74 billion a year earlier.

Analysts surveyed by Capital IQ expected $28.49 billion.

The company said it continues to expect 2024 adjusted earnings of roughly $16 per diluted share. Analysts polled by Capital IQ expect $16.13.

Humana's shares rose 3.2% in recent premarket activity.

Price: 338.50, Change: +10.52, Percent Change: +3.21

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Dec 16, 2024
Dec 16 (Reuters) - Regional lenders Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the companies said on Monday. ...
Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder
Mind Medicine Doses First Patient in Phase 3 Study of MM120 to Treat Generalized Anxiety Disorder
Dec 16, 2024
08:35 AM EST, 12/16/2024 (MT Newswires) -- Mind Medicine (MNMD) said Monday that a first patient has been dosed in its phase 3 Voyage study that is evaluating MM120 ODT for the treatment of generalized anxiety disorder. The company said the trial is the first of two phase 3 studies evaluating the efficacy and safety of MM120 ODT versus placebo....
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Biohaven ( BHVN ) said Monday that its drug candidate BHV-1300 achieved deep lowering of targeted immunoglobulin G, or IgG, with reduction of more than 60% in the lowest subcutaneous dose tested during the current multiple ascending dose trial. The biopharmaceutical company said that the reduction in IgG occurred within hours of each...
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Gatos Silver ( GATO ) said Friday that the proposed acquisition of the company by First Majestic (AG) was given unconditional authorization by the Mexican Federal Economic Competition Commission. The transaction is expected to close in January. ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved